Biotech stocks' K-line charts look terrible, the waters are too deep, and one careless move can lead to a 50% drop. You think you're buying a company, but you're actually just buying a trial result. QURE had super strong data for a drug in the first 3 years, but in the 4th year, the control group changed, leading to reduced efficacy data and a 40% stock price crash. Better stick to buying the XLV healthcare ETF!